Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 April 2006Website:
http://www.vandapharma.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 32 min agoDividend
Analysts recommendations
Institutional Ownership
VNDA Latest News
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 financial results and other corporate activities.
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What type of business is Vanda Pharmaceuticals?
Vanda Pharmaceuticals Inc. is an American biopharmaceutical company headquartered in Washington, D.C., developing and commercializing innovative drugs for the treatment of neurological disorders. It was founded in 2003. Currently, the company's product portfolio includes the following products: HETLIOZ and Fanapt. In addition, Vanda Pharmaceuticals Inc. is developing a range of medications, including: HETLIOZ for the treatment of disorders related to changing time zones and Smith-Magenis syndrome, Fanapt for the treatment of bipolar disorder, Tradipitant for the treatment of atopic dermatitis, gastroparesis, and motion sickness, VTR-297 for the treatment of hematologic malignancies and with potential use in the treatment of several oncological diseases, among others.
What sector is Vanda Pharmaceuticals in?
Vanda Pharmaceuticals is in the Healthcare sector
What industry is Vanda Pharmaceuticals in?
Vanda Pharmaceuticals is in the Biotechnology industry
What country is Vanda Pharmaceuticals from?
Vanda Pharmaceuticals is headquartered in United States
When did Vanda Pharmaceuticals go public?
Vanda Pharmaceuticals initial public offering (IPO) was on 12 April 2006
What is Vanda Pharmaceuticals website?
https://www.vandapharma.com
Is Vanda Pharmaceuticals in the S&P 500?
No, Vanda Pharmaceuticals is not included in the S&P 500 index
Is Vanda Pharmaceuticals in the NASDAQ 100?
No, Vanda Pharmaceuticals is not included in the NASDAQ 100 index
Is Vanda Pharmaceuticals in the Dow Jones?
No, Vanda Pharmaceuticals is not included in the Dow Jones index
When was Vanda Pharmaceuticals the previous earnings report?
No data
When does Vanda Pharmaceuticals earnings report?
The next expected earnings date for Vanda Pharmaceuticals is 06 November 2024